These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 21347617)

  • 1. Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.
    Krishna R; Bergman AJ; Green M; Dockendorf MF; Wagner JA; Dykstra K
    AAPS J; 2011 Jun; 13(2):179-90. PubMed ID: 21347617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
    Kühnast S; van der Tuin SJ; van der Hoorn JW; van Klinken JB; Simic B; Pieterman E; Havekes LM; Landmesser U; Lüscher TF; Willems van Dijk K; Rensen PC; Jukema JW; Princen HM
    Eur Heart J; 2015 Jan; 36(1):39-48. PubMed ID: 25142968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
    Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    Am J Cardiol; 2014 Jan; 113(1):76-83. PubMed ID: 24188894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E.
    Millar JS; Lassman ME; Thomas T; Ramakrishnan R; Jumes P; Dunbar RL; deGoma EM; Baer AL; Karmally W; Donovan DS; Rafeek H; Wagner JA; Holleran S; Obunike J; Liu Y; Aoujil S; Standiford T; Gutstein DE; Ginsberg HN; Rader DJ; Reyes-Soffer G
    J Lipid Res; 2017 Jun; 58(6):1214-1220. PubMed ID: 28314859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA; Davis K
    Vasc Health Risk Manag; 2012; 8():483-93. PubMed ID: 22977305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
    Lauring B; Liu Y; Li XS; Larson P; Moreau A; Farmer HF; Johnson-Levonas AO; Wagner JA; Lai E
    J Clin Pharmacol; 2014 Jul; 54(7):765-75. PubMed ID: 24615657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib.
    Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP
    Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of anacetrapib on plasma lipids, apolipoproteins and PCSK9 in healthy, lean rhesus macaques.
    Roddy TP; McLaren DG; Chen Y; Xie D; Dunn K; Kulick A; Szeto D; Forrest G; Albanese K; Donnelly M; Gai C; Gewain A; Lederman H; Jensen KK; Ai X; Vachal P; Akinsanya KO; Cleary MA; Previs SF; Dansky HM; Johns DG
    Eur J Pharmacol; 2014 Oct; 740():410-6. PubMed ID: 24769414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.
    Teramoto T; Shirakawa M; Kikuchi M; Nakagomi M; Tamura S; Surks HK; McCrary Sisk C; Numaguchi H
    Atherosclerosis; 2013 Sep; 230(1):52-60. PubMed ID: 23958252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial.
    Metzinger MP; Saldanha S; Gulati J; Patel KV; El-Ghazali A; Deodhar S; Joshi PH; Ayers C; Rohatgi A
    J Am Heart Assoc; 2020 Dec; 9(24):e018136. PubMed ID: 33263263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of In-Stent Restenosis by Cholesteryl Ester Transfer Protein Inhibition.
    Wu BJ; Li Y; Ong KL; Sun Y; Shrestha S; Hou L; Johns D; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2017 Dec; 37(12):2333-2341. PubMed ID: 29025709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.